Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 3/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19345927 | 0.90 | CAPN1 (0.39) | CAPN1CTSKCA1CA2CA7 | |
| SCHEMBL19346052 | 0.89 | TDP1 (0.39) | CAPN1CTSKCA1CA2CA7 | |
| SCHEMBL19345932 | 0.80 | CA1 (0.42) | CAPN1CTSKCA1CA2CA7 | |
| SCHEMBL13223285 | 0.80 | REN (0.39) | CTSKRENCTSSMAPTMEN1 | |
| SCHEMBL24072259 | 0.77 | TDP1 (0.49) | CA1CA2ALDH1A1LMNAMAPT | |
| SCHEMBL19345914 | 0.74 | CA1 (0.46) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL13223277 | 0.74 | CA1 (0.46) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL8051422 | 0.74 | ALDH1A1 (0.43) | CTSKCA1CA2CA7ALDH1A1 | |
| SCHEMBL29458939 | 0.73 | CA1 (0.45) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL7441196 | 0.71 | CA1 (0.49) | CTSKCA1CA2CA7CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CAPN1 3519/4885CTSK 1630/4885CA1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.